Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026
Rhea-AI Summary
Krystal Biotech (NASDAQ: KRYS) will report first quarter 2026 financial results on Monday, May 4, 2026, released prior to the open of U.S. markets.
Management will host a conference call and webcast at 8:30 AM ET on May 4, 2026 to discuss results and provide a business update. A replay will be available for at least 30 days on the company investor website.
Positive
- None.
Negative
- None.
News Market Reaction – KRYS
In the Apr 21 session, KRYS declined 1.39%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Earnings date notice | Neutral | -0.7% | Set reporting date and webcast details for Q4 and FY2025 results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited history for 'earnings date' releases shows a small, negative move on the prior event, suggesting these scheduling notices have had minimal impact.
This announcement schedules Krystal Biotech’s Q1 2026 earnings release and call, similar to the prior notice on February 10, 2026 ahead of Q4 and full-year 2025 results. That earlier earnings-date release saw a modest -0.7% move, while the subsequent earnings report highlighted strong VYJUVEK revenues and cash. Alongside positive regulatory and clinical updates in early 2026, this continues a pattern of regular, structured communication around financial milestones.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May 4, 2026, prior to the open of U.S. markets.
The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, May 4, 2026, to discuss the financial results and provide a business update.
Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53916.
For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at www.krystalbio.com.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com
